Tuesday, June 12, 2018

On the Record


"You'd be hard pressed today to find an unattractive PBM asset."

— Ashraf Shehata, a principal in KPMG's health care life sciences advisory practice, describing the M&A climate among PBMs to Radar on Drug Benefits

No comments:

Post a Comment